1. Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro.
- Author
-
Ganassin, Rayane, Merker, Carolin, Rodrigues, Mosar Corrêa, Guimarães, Nayara Felipe, Sodré, Carine Sampaio Cerqueira, Ferreira, Queila da Silva, da Silva, Sebastião William, Ombredane, Alicia Simalie, Joanitti, Graziella Anselmo, Py-Daniel, Karen Rapp, Zhang, Juan, Jiang, Cheng-Shi, de Morais, Paulo César, Mosiniewicz-Szablewska, Ewa, Suchocki, Piotr, Longo, João Paulo Figueiró, Meijer, Jan, Estrela-Lopis, Irina, de Azevedo, Ricardo Bentes, and Muehlmann, Luis Alexandre more...
- Subjects
DOXORUBICIN ,BREAST cancer - Abstract
Nanocapsules (NCS-DOX) with an oily core of selol and a shell of poly(methyl vinyl ether-co-maleic anhydride) covalently conjugated to doxorubicin were developed. These nanocapsules are spherical, with an average hydrodynamic diameter of about 170 nm, and with negative zeta potential. NCS-DOX effectively co-delivered the selol and the doxorubicin into 4T1 cells and changed the intracellular distribution of DOX from the nuclei to the mitochondria. Moreover, a significantly increased cytotoxicity against 4T1 cells was observed, which is suggestive of additive or synergic effect of selol and doxorubicin. In conclusion, PVM/MA nanocapsules are suitable platforms to co-deliver drugs into cancer cells. [ABSTRACT FROM AUTHOR] more...
- Published
- 2018
- Full Text
- View/download PDF